The histological analysis showed the effects of co-administering PDT with oxaliplatin and gemcitabine on tumor necrosis, cell apoptosis, proliferating cell nuclear antigen labeling index (PCNA LI), and percentage of the VEGF-immunopositive area (PVIA) (%). Here, PCNA is linked to neoplasm.